Study S001537

Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05606913
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 731
Start: 2023-01-06
Primary completion: 2024-01-26
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:dulaglutide; DRUG:IBI362
Results posted: FALSE

Registered primary outcomes

HbA1c change from baseline at week 28 [Baseline, 28 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007335	Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Guo L, Nature	2026	Randomized trial	PMID 41407860 DOI	cites ClinicalTrials.gov:NCT05606913; registry reference DERIVED:41407860